JP2004523594A5 - - Google Patents

Download PDF

Info

Publication number
JP2004523594A5
JP2004523594A5 JP2002578923A JP2002578923A JP2004523594A5 JP 2004523594 A5 JP2004523594 A5 JP 2004523594A5 JP 2002578923 A JP2002578923 A JP 2002578923A JP 2002578923 A JP2002578923 A JP 2002578923A JP 2004523594 A5 JP2004523594 A5 JP 2004523594A5
Authority
JP
Japan
Prior art keywords
component
dosage form
pharmaceutical dosage
form according
sorbitan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002578923A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004523594A (ja
Filing date
Publication date
Priority claimed from GBGB0107106.7A external-priority patent/GB0107106D0/en
Application filed filed Critical
Publication of JP2004523594A publication Critical patent/JP2004523594A/ja
Publication of JP2004523594A5 publication Critical patent/JP2004523594A5/ja
Pending legal-status Critical Current

Links

JP2002578923A 2001-03-21 2002-03-16 粉末吸入製剤 Pending JP2004523594A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0107106.7A GB0107106D0 (en) 2001-03-21 2001-03-21 Powder inhaler formulations
PCT/EP2002/002948 WO2002080884A2 (en) 2001-03-21 2002-03-16 Powder inhaler formulations

Publications (2)

Publication Number Publication Date
JP2004523594A JP2004523594A (ja) 2004-08-05
JP2004523594A5 true JP2004523594A5 (cg-RX-API-DMAC7.html) 2009-07-23

Family

ID=9911273

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002578923A Pending JP2004523594A (ja) 2001-03-21 2002-03-16 粉末吸入製剤

Country Status (10)

Country Link
US (3) US20030007932A1 (cg-RX-API-DMAC7.html)
EP (1) EP1372610B1 (cg-RX-API-DMAC7.html)
JP (1) JP2004523594A (cg-RX-API-DMAC7.html)
AT (1) ATE556704T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002316820A1 (cg-RX-API-DMAC7.html)
CA (1) CA2440010C (cg-RX-API-DMAC7.html)
GB (1) GB0107106D0 (cg-RX-API-DMAC7.html)
MX (1) MXPA03008398A (cg-RX-API-DMAC7.html)
UY (1) UY27218A1 (cg-RX-API-DMAC7.html)
WO (1) WO2002080884A2 (cg-RX-API-DMAC7.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CN102688224A (zh) * 2003-04-14 2012-09-26 维克特拉有限公司 用于提高剂量效率的药物组合物和装置
SE0302665D0 (sv) 2003-10-07 2003-10-07 Astrazeneca Ab Novel Process
ITMI20040795A1 (it) * 2004-04-23 2004-07-23 Eratech S R L Composizione farmaceutica solida secca suo processo di preparazione e sospensione acquosa stabile ottenuta dalla stessa
DE102004024451A1 (de) * 2004-05-14 2005-12-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierungen für die Inhalation, die Enantiomerenreine Betaagonisten enthalten
US9149433B2 (en) * 2004-11-30 2015-10-06 Basf Corporation Method for formation of micro-prilled polymers
BRPI0606364A2 (pt) 2005-02-10 2010-03-23 Glaxo Group Ltd processo para formar lactose adequada para uso em uma formulaÇço farmacÊutica
EP1917253B1 (de) 2005-08-15 2015-01-07 Boehringer Ingelheim International Gmbh Verfahren zur herstellung von betamimetika
EP1925295A1 (de) * 2006-11-22 2008-05-28 Boehringer Ingelheim Pharma GmbH & Co. KG Stabile Pulverformulierung enthaltend ein Anticholinergikum
CN101861311A (zh) 2007-07-21 2010-10-13 阿尔巴尼分子研究公司 5-吡啶酮取代的吲唑
CN103351390A (zh) 2007-11-21 2013-10-16 解码遗传Ehf公司 用于治疗肺部和心血管病症的联芳基pde4 抑制剂
CA2727055C (en) 2008-01-11 2016-12-20 Albany Molecular Research, Inc. (1-azinone) -substituted pyridoindoles as mch antagonists
EP2349224B1 (en) 2008-10-10 2017-05-10 Probelte Pharma, S.A. Orally administrable immunostimulant product for aquaculture
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
WO2010084499A2 (en) 2009-01-26 2010-07-29 Israel Institute For Biological Research Bicyclic heterocyclic spiro compounds
WO2010102065A1 (en) 2009-03-05 2010-09-10 Bend Research, Inc. Pharmaceutical compositions of dextran polymer derivatives
PT3130396T (pt) 2009-03-27 2021-05-12 Bend Res Inc Processo de secagem por pulverização
TR200909788A2 (tr) 2009-12-25 2011-07-21 Bi̇lgi̇ç Mahmut Tiotropyum içeren inhalasyona uygun kuru toz formülasyonu
US8834931B2 (en) 2009-12-25 2014-09-16 Mahmut Bilgic Dry powder formulation containing tiotropium for inhalation
WO2012031129A2 (en) 2010-09-03 2012-03-08 Bend Research, Inc. Spray-drying apparatus and methods of using the same
WO2012031133A2 (en) 2010-09-03 2012-03-08 Bench Research, Inc. Spray-drying apparatus and methods of using the same
US8815294B2 (en) 2010-09-03 2014-08-26 Bend Research, Inc. Pharmaceutical compositions of dextran polymer derivatives and a carrier material
US9248584B2 (en) 2010-09-24 2016-02-02 Bend Research, Inc. High-temperature spray drying process and apparatus
US9060938B2 (en) 2011-05-10 2015-06-23 Bend Research, Inc. Pharmaceutical compositions of active agents and cationic dextran polymer derivatives
US10105500B2 (en) 2012-05-09 2018-10-23 Virginia Commonwealth University Dry powder inhaler (DPI) designs for producing aerosols with high fine particle fractions
JP6233853B2 (ja) * 2012-05-14 2017-11-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 薬剤入りブリスタを収容する器具
US10105316B2 (en) 2012-07-05 2018-10-23 Arven llac Sanayi Ve Ticaret A.S. Inhalation compositions comprising muscarinic receptor antagonist
US10111957B2 (en) * 2012-07-05 2018-10-30 Arven Ilac Snayi ve Ticaret A.S. Inhalation compositions comprising glucose anhydrous
AU2015338717B2 (en) 2014-10-31 2018-12-20 Glaxosmithkline Intellectual Property Development Limited Powder formulation
CA2962719A1 (en) 2014-10-31 2016-05-06 Bend Research Inc. Process for forming active domains dispersed in a matrix
US11844859B2 (en) 2017-08-20 2023-12-19 Nasus Pharma Ltd. Dry powder compositions for intranasal delivery
CN110996912A (zh) * 2017-08-20 2020-04-10 福摩莱克斯医药创新有限公司 用于鼻内递送的干粉组合物
ES3038913T3 (en) 2018-03-20 2025-10-15 Icahn School Med Mount Sinai Beta-carboline derivatives as dyrk1a inhibitors for the treatment of e.g. diabetes
US11786460B2 (en) * 2018-04-16 2023-10-17 Ioulia Tseti Pharmaceutical dry powder composition for inhalation comprising a thyroid hormone
AU2019334202A1 (en) 2018-09-06 2021-03-25 Innopharmascreen, Inc. Methods and compositions for treatment of asthma or parkinson's disease
CA3124700A1 (en) 2018-12-31 2020-07-09 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
TW202541834A (zh) * 2024-04-16 2025-11-01 南韓商韓美藥品股份有限公司 吸入用組成物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL263733A (cg-RX-API-DMAC7.html) * 1960-04-19 1900-01-01
DE3013839A1 (de) * 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
US4533542A (en) * 1983-08-22 1985-08-06 Eli Lilly And Company Pharmaceutical compositions for storage in plastic containers and process therefor
GB9024366D0 (en) * 1990-11-09 1991-01-02 Glaxo Group Ltd Medicaments
GB9026025D0 (en) * 1990-11-29 1991-01-16 Boehringer Ingelheim Kg Inhalation device
US5354934A (en) * 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
US6645644B1 (en) * 1996-10-17 2003-11-11 The Trustees Of Princeton University Enhanced bonding of phosphoric and phosphoric acids to oxidized substrates
US5874111A (en) * 1997-01-07 1999-02-23 Maitra; Amarnath Process for the preparation of highly monodispersed polymeric hydrophilic nanoparticles
DE69732306T2 (de) * 1997-01-16 2006-01-12 Massachusetts Institute Of Technology, Cambridge Zubereitung von partikelhaltigen arzneimitteln zur inhalation
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
ATE248583T1 (de) * 1997-09-29 2003-09-15 Nektar Therapeutics In dosierinhalatoren verwendbare, stabilisierte zubereitungen
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
CN1150895C (zh) * 1998-11-13 2004-05-26 杰格研究股份公司 用于吸入给药的干粉
EG23951A (en) * 1999-03-25 2008-01-29 Otsuka Pharma Co Ltd Cilostazol preparation

Similar Documents

Publication Publication Date Title
JP2016028068A5 (cg-RX-API-DMAC7.html)
KR101381263B1 (ko) 구연산, 산화 마그네슘, 중탄산칼륨 및 피코황산나트륨을 포함하는 의약품의 제조 방법, 이러한 방법에 의해 제조된 과립을 포함하는 약제학적 조성물 및 중간체
RU2014150986A (ru) Вдыхаемые частицы, содержащие тиотропий
CA2440010A1 (en) Powder inhaler formulations
CN116075306B (zh) 用于治疗冠状病毒感染的化合物
CN1682707A (zh) 含有非诺贝特的药物组合物及其制备方法
JPS6147807B2 (cg-RX-API-DMAC7.html)
JP2013508344A5 (cg-RX-API-DMAC7.html)
JP2002506017A (ja) ニコチン吸入器
JP2716155B2 (ja) ベーター−2−ミメテイツクスのガレン製剤及びその製造方法
WO2010102066A1 (en) Dextran polymer powder for inhalation administration of pharmaceuticals
CN105361242A (zh) 一种基于液体弹珠的多功能型香烟爆珠及其制备方法
JP2017532374A5 (cg-RX-API-DMAC7.html)
JP2012509922A5 (cg-RX-API-DMAC7.html)
CN116963738A (zh) 用于SARS-CoV-2感染的后遗症的预防和治疗的鲁米诺
CN115052602A (zh) 5-胺基-2,3-二氢-1,4-酞嗪二酮在治疗罕见的慢性发炎性肺病中的用途
CN112451509A (zh) 一种川丁特罗吸入粉雾剂及其制备方法
JP2002102336A (ja) 固形透析用製剤およびその製造方法
CN1291097A (zh) 硫酸吗啡微粒、其制备方法和药物制剂
JP2005505560A (ja) 三環系5,6−ジヒドロ−9H−ピラゾロ(3,4−c)−1,2,4−トリアゾロ(4,3−アルファ)ピリジンを含む吸入組成物
RU2006133543A (ru) Фармацевтическая композиция для орального применения и способ ее приготовления
CN101773478A (zh) 一种兽用头孢噻呋盐酸盐的肺靶向微球及制备方法
CA2670155C (en) Stable powder formulation containing an anticholinergic agent
JP2008007523A (ja) 固形重曹透析用剤
CN1634006A (zh) 盐酸文拉法辛液体缓释制剂及其制备方法